SHMT1: A Promising Drug Target for Various Diseases (G6470)

Target Name: SHMT1

NCBI ID: G6470

SHMT1

SHMT1: A Promising Drug Target for Various Diseases

SHMT1 (GLYC-HUMAN), a protein that belongs to the family of transmembrane proteins known as GLYC proteins, is a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SHMT1 is a 21-kDa protein that is expressed in various tissues of the human body, including the brain, pancreas, and heart. It is involved in the regulation of cellular processes that are essential for the normal functioning of tissues, including cell signaling, protein synthesis, and intracellular signaling.

One of the key functions of SHMT1 is its role in the regulation of pancreatic insulin secretion. SHMT1 has been shown to play a critical role in the regulation of insulin secretion from pancreatic beta cells, which is the primary site of insulin production in the body.

In neurodegenerative diseases, SHMT1 has been implicated in the development and progression of various disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. SHMT1 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as in the regulation of cellular signaling pathways that are involved in the development of neurodegenerative diseases.

In addition to its role in neurodegenerative diseases, SHMT1 has also been implicated in the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. SHMT1 has been shown to play a critical role in the regulation of immune cell function, as well as in the regulation of inflammation.

Despite the potential implications of SHMT1 as a drug target and biomarker, much research is still needed to fully understand its role in various diseases.SHMT1 has been shown to be involved in a wide range of cellular processes that are essential for the normal functioning of tissues, including cell signaling, protein synthesis, and intracellular signaling.

In addition to its role in neurodegenerative diseases, SHMT1 has also been implicated in the development and progression of various autoimmune disorders.

Overall, SHMT1 is a promising drug target and biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Serine Hydroxymethyltransferase 1

Functions: Interconversion of serine and glycine (PubMed:8505317, PubMed:24698160)

The "SHMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets